For its part, Takeda recently scaled back its cell therapy pipeline in a cull that saw TAK-102 discontinued. The project had been licensed from the Japanese group Noile-Immune Biotech in 2017, and Takeda put it into phase 1.
The abstract of an ASCO poster on TAK-102 details those phase 1 data, and while there are also no DLTs or neurotoxicity there aren’t any responses either, the best result among 11 solid tumour patients being stable disease. TAK-102, which after Takeda's discontinuation remains in Noile-Immune's pipeline as NIB102, is also “armoured”, but encodes IL-7 and CCL20 rather than TGFβRIIDN.
The ASCO data might also be of interest to Gilead, which in an April 2022 oncology deep dive presented the Car-T therapy KITE-509, which targets GPC3 and also blocks the TGFβ signal. However, despite Gilead promising clinical trials “in the near future” these have yet to materialise.
Takeda out
For its part, Takeda recently scaled back its cell therapy pipeline in a cull that saw TAK-102 discontinued. The project had been licensed from the Japanese group Noile-Immune Biotech in 2017, and Takeda put it into phase 1.
The abstract of an ASCO poster on TAK-102 details those phase 1 data, and while there are also no DLTs or neurotoxicity there aren’t any responses either, the best result among 11 solid tumour patients being stable disease. TAK-102, which after Takeda's discontinuation remains in Noile-Immune's pipeline as NIB102, is also “armoured”, but encodes IL-7 and CCL20 rather than TGFβRIIDN.
The ASCO data might also be of interest to Gilead, which in an April 2022 oncology deep dive presented the Car-T therapy KITE-509, which targets GPC3 and also blocks the TGFβ signal. However, despite Gilead promising clinical trials “in the near future” these have yet to materialise.
武田薬品の撤退
武田薬品は最近、TAK-102の開発中止を含む細胞治療パイプラインの縮小を行った。 このプロジェクトは2017年に日本のNoile-Immune Biotechグループからライセンスを受け、武田薬品はそれを第1相試験に投入した。
TAK-102に関するASCOポスターの要旨には、これらの臨床第1相試験のデータが詳細に記載されており、DLTや神経毒性もないが、奏効もなく、11人の固形がん患者の中で最も良好な結果は病勢安定であった。 TAK-102は、武田薬品の販売中止後もNIB102としてノイル-イミューン社のパイプラインに残っており、同じく「アーマード」であるが、TGFβRIIDNではなくIL-7とCCL20をコードしている。
ASCOのデータは、ギリアド社にとっても興味深いかもしれない。ギリアド社は、2022年4月のがん領域におけるディープダイブで、GPC3を標的とし、TGFβシグナルも遮断するCar-T療法KITE-509を発表した。 しかし、ギリアド社は「近い将来」の臨床試験を約束しているにもかかわらず、まだ実現していない。
https://www.oncologypipeline.com/apexonco/asco-2024-preview-new-car-t-target-shows-liver-cancer-promise